AURA News and Press, Aura Biosciences Inc.

Enrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trial Topline data from the 15-month primary endpoint expected in the second half of 2027 BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology c...

BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that inducement equ...

2026-05-12 15:15:03 ET from Leerink Partners issued a price target of $17.00 for AURA on 2026-05-12 17:55:24. The adjusted price target was set to $17.00. At the time of the announcement, AURA was trading at $7.899. The overall price target consensus is at $22.75 with hi...

2026-05-11 16:56:08 ET More on Aura Biosciences Aura Biosciences prices $260M stock, warrant offering Seeking Alpha’s Quant Rating on Aura Biosciences Historical earnings data for Aura Biosciences Financial information for Aura Biosciences Re...

Phase 3 CoMpass trial advancing toward enrollment completion, supporting 2H 2027 topline data Natalie Holles appointed Chief Executive Officer and President and member of the Board of Directors Strengthened balance sheet with oversubscribed $299 million equity financing; cash position exp...

BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the closing of its previously announced underwritten p...

2026-05-04 09:10:42 ET More on Aura Biosciences Seeking Alpha’s Quant Rating on Aura Biosciences Historical earnings data for Aura Biosciences Financial information for Aura Biosciences Read the full article on Seeking Alpha For further details...

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing of an underwritten public offering consist...

2026-05-04 06:17:59 ET More on Aura Biosciences Seeking Alpha’s Quant Rating on Aura Biosciences Historical earnings data for Aura Biosciences Financial information for Aura Biosciences Read the full article on Seeking Alpha For further details...

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the launch of an underwritten public offering of share...